Robert F. Kennedy Jr.

They're not allowed to say, well, we don't believe these are efficacious or whatever.

They can only look at safety.

They move those to category two, which means to not formulate.

What happened?

There was huge demand for peptides.

And so a black market came out.

And the black market is run by

companies that say that they're making the peptides for animal use or for research purposes.

And that peptide now basically completely replaced the legal market.

The legal market for peptides, the pharmacies, the compounding pharmacies,

We're getting those peptides from FDA-inspected facilities, and some of them in India and China, but they were the same one that the pharmaceutical industries are buying them, and we inspect those.

You know you're getting a good product.

You know you're getting what you bought, what was advertised.

With the gray market, you have no idea.

And a lot of this stuff that we've looked at is just, you know, is very, very substandard.

I'm very anxious to move, probably not all of those peptides, some of them are in litigation, but about 14 of them back to making them more accessible.

And FDA is in the middle of, I think, within a couple of weeks, we will have announced some kind of new action.

And my hope is that

They're going to end up with – they're still looking at the science.

My hope is that they're going to get moved to a place where people have access from ethical suppliers.